FOLD - NASDAQ

Amicus Therapeutics, Inc.

FOLD·NASDAQ

$14.49

+0.0000%

HealthcareBiotechnology

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$4.55B

EPS-0.0879

P/E Ratio-164.85

Earnings Date05/07/2026

949.87M

Assets

21%

3Y+31.0%

5Y+7.0%

10Y-8.0%

675.63M

Total Liabilities

14%

3Y+12.0%

5Y+13.0%

10Y-

274.24M

Total Equity

41%

3Y+123.0%

5Y-4.0%

10Y-24.0%

Amicus Therapeutics, Inc. Funding & Solvency Profile

FOLD · NASDAQ

Current Assets

Cash & Cash Equivalents214.01M

Net Receivables115.31M

Inventory228.82M

Other Current Assets38.51M

Total Current Assets676 M

Non-Current Assets

Property, Plant & Equipment48.25M

Goodwill & Intangible Assets211.71M

Long-Term Investments0.00

Other Non-Current Assets13.74M

Total Non-Current Assets62 M

Total Assets

949.87M

Financial Health Analysis

Current Ratio

2.84x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

2.46x

High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.

Working Capital

438 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

71% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Mixed signals: Strong short-term liquidity provides comfort, but high overall leverage requires careful monitoring of debt servicing capabilities and refinancing risk.

Amicus Therapeutics, Inc. Balance Sheet

FOLD • NASDAQ

Amicus Therapeutics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	214M	213.8M	247M	148.8M	245.2M	163.2M	142.8M	79.7M	49.1M	187M	69.5M	24.1M	43.6M	34M	25.7M	29.6M	19.3M	28.1M	44.2M	12.1M
Short-Term Investments	79.5M	36.2M	39.2M	144.8M	237.3M	320M	309.9M	424.4M	309.5M	143.3M	144.5M	127.6M	38.4M	65.2M	30M	77.9M	58.9M	93.1M	117.3M	42.6M
Cash & Short-Term Investments	293.5M	249.9M	286.2M	293.6M	482.5M	483.3M	452.7M	504.2M	358.6M	330.4M	214M	151.7M	82M	99.1M	55.7M	107.4M	78.2M	121.1M	161.5M	54.7M
Net Receivables	115.3M	101.1M	87.6M	66.2M	52.7M	46.9M	33.3M	22M	9.5M	1.3M	0.0	0.0	1.1M	3.2M	5M	0.0	0.0	0.0	0.0	0.0
Accounts Receivables	115.3M	101.1M	87.6M	66.2M	52.7M	46.9M	33.3M	22M	9.5M	1.3M	0.0	0.0	1.1M	3.2M	5M	0.0	0.0	0.0	0.0	0.0
Inventory	228.8M	118.8M	59.7M	23.8M	26.8M	19.6M	14M	8.4M	4.6M	3.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	0.0	0.0	0.0	34.8M	29.7M	20M	16.6M	19.3M	5M	2.6M	2.9M	5.2M	2.3M	5.9M	2.2M	2.3M	2.5M	1.5M	321K
Other Current Assets	38.5M	34.9M	49.5M	40.2M	0.0	0.0	0.0	16.6M	19.3M	5M	2.6M	2.9M	0.0	2.3M	0.0	0.0	0.0	2.5M	1.5M	0.0
Total Current Assets	676.2M	504.7M	483.1M	423.8M	596.8M	579.5M	520.1M	551.1M	392M	340.1M	216.6M	154.6M	88.3M	104.6M	66.6M	109.7M	80.5M	123.6M	163M	55M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	48.2M	51.7M	58M	60.3M	63.1M	67.2M	81M	11.4M	9.1M	9.8M	6.2M	2.8M	4.1M	5M	2.4M	2.6M	4.4M	4.9M	3.8M	4.4M
Goodwill	197.8M	197.8M	197.8M	197.8M	197.8M	197.8M	197.8M	197.8M	197.8M	197.8M	197.8M	11.6M	11.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Intangible Assets	13.9M	17.2M	20.5M	23M	23M	23M	23M	23M	23M	486.7M	486.7M	23M	23M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	211.7M	215M	218.3M	220.8M	220.8M	220.8M	220.8M	220.8M	220.8M	684.5M	684.5M	34.6M	34.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Long-Term Investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.5M	-6.5M	-173.8M	0.0	17.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.5M	6.5M	173.8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	13.7M	13.6M	18.6M	19.2M	24.4M	19.1M	28.3M	6.7M	5.2M	2.5M	1.1M	502K	552K	442K	709K	267K	485K	267K	267K	267.3K
Total Non-Current Assets	273.7M	280.3M	294.8M	300.4M	308.3M	307.1M	330.1M	238.9M	235.1M	696.8M	691.8M	55.4M	39.3M	5.5M	3.1M	2.9M	4.9M	5.2M	4.1M	4.6M
Total Assets	949.9M	785M	777.9M	724.2M	905.1M	886.5M	850.2M	790M	627M	1B	908.4M	210M	127.6M	110.1M	69.8M	112.6M	85.4M	128.8M	167.1M	59.6M
LIABILITIES
CURRENT LIABILITIES
Total Payables	57.4M	31.1M	27.6M	42.8M	51.1M	43.7M	34.2M	12.4M	18.8M	69.5M	16.5M	5.9M	2.1M	2.1M	2.6M	0.0	0.0	2M	530K	1.2M
Accounts Payable	28.6M	12.9M	15.1M	15.4M	21.5M	17.1M	21.7M	6.6M	7.9M	12.9M	16.5M	5.9M	2.1M	2.1M	2.6M	0.0	0.0	2M	530K	1.2M
Other Payables	28.8M	18.1M	12.4M	27.4M	29.6M	26.6M	12.5M	5.8M	10.9M	56.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	636.0
Accrued Expenses	37.7M	68M	83.1M	54.5M	59M	52M	56.2M	41.7M	20.1M	17.4M	6.2M	5.1M	4.8M	4.2M	4M	0.0	0.0	0.0	2.3M	1.2M
Short Term Debt	8.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.8M	299K	398K	1M	1.3M	1.3M	877K	1.5M	1.3M
Capital Lease Obligations (Current)	0.0	8.5M	8.3M	8.6M	7.4M	6.9M	7.2M	0.0	307K	283K	0.0	0.0	0.0	0.0	0.0	40K	305K	877K	0.0	0.0
Tax Payables	0.0	18.1M	12.4M	5.9M	6.2M	11.2M	7.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.5M	7.8M	69.4M	0.0	-10.5M	0.0	-6.7M	8.5M	6.6M	0.0	3.7M	3.8M	0.0
Other Current Liabilities	134M	41.2M	48.7M	33.2M	28.5M	27.1M	31.2M	32.1M	30.8M	23.8M	50.9M	5.4M	3.2M	2.5M	3.2M	8.3M	9.6M	5.9M	7.7M	6.5M
Total Current Liabilities	237.8M	148.7M	167.7M	139M	146M	129.7M	128.8M	86.1M	70M	111M	73.6M	20.2M	10.5M	9.2M	19.3M	16.2M	11.2M	13.4M	15.8M	10.2M
NON-CURRENT LIABILITIES
Long Term Debt	433.6M	390.1M	387.9M	392M	389.4M	389.3M	149.5M	321.7M	164.2M	154.5M	41.6M	10.5M	14.2M	299K	0.0	1M	2.3M	0.0	0.0	0.0
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	29.9M	31.2M	235.5M	269.1M	47.3M	47.3M	0.0	19M	25.6M	0.0	44M	46.8M	0.0
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	4.9M	4.9M	4.9M	5.1M	6.5M	6.5M	173.8M	176.2M	9.2M	9.2M	0.0	0.0	0.0	0.0	-44M	-46.8M	0.0
Other Non-Current Liabilities	-36.8M	7.1M	13.3M	13.6M	14.1M	30.7M	36.9M	32.7M	33.5M	237.5M	269.1M	47.9M	48M	31.3M	1.9M	4.7M	0.0	0.0	0.0	124.7M
Total Non-Current Liabilities	437.8M	442.3M	450M	462.1M	451.8M	470.5M	245M	360.9M	204.1M	565.7M	486.9M	67.6M	71.4M	31.6M	20.9M	31.4M	2.3M	44.4M	48M	127M
Capital Lease Obligations	41M	53.5M	57.2M	60.1M	50.8M	52.5M	60.7M	0.0	307K	283K	0.0	0.0	0.0	0.0	40K	40K	353K	317K	1.2M	2.3M
Total Liabilities	675.6M	591M	617.7M	601.1M	597.8M	600.1M	373.8M	447M	274.2M	676.7M	560.6M	87.8M	81.8M	40.9M	40.2M	47.6M	13.5M	57.7M	63.8M	137.2M
SHAREHOLDERS' EQUITY
Treasury Stock	-71K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	778.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Common Stock	3M	2.9M	2.9M	2.8M	2.8M	2.7M	2.6M	1.9M	1.7M	1.5M	1.3M	1M	679K	556K	407K	406K	287K	287K	285K	70.3K
Additional Paid-In Capital	3B	2.9B	2.8B	2.7B	2.6B	2.3B	2.2B	1.7B	1.4B	1.1B	917.5M	568.7M	423.6M	387.5M	299.3M	290.2M	242.3M	234.4M	227.4M	6.1M
Retained Earnings	-2.8B	-2.7B	-2.7B	-2.5B	-2.3B	-2B	-1.8B	-1.4B	-1.1B	-779.6M	-579.6M	-447.4M	-378.5M	-318.9M	-270.1M	-225.7M	-170.8M	-164.2M	-124.8M	-83.7M
Accumulated Other Comprehensive Income/Loss	24.1M	5.1M	5.2M	-12.1M	5M	8.2M	2.8M	68K	-2.1M	2M	-115K	-132K	1K	14K	4K	-28K	43K	533K	408K	14.8K
Other Total Stockholders' Equity	0.0	71K	71K	83K	83K	12.4M	12.4M	0.0	0.0	0.0	8.8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	217M
Total Stockholders' Equity	274.2M	194M	160.2M	123M	307.4M	286.4M	476.4M	342.9M	352.9M	360.2M	347.8M	122.2M	45.8M	69.2M	29.6M	64.9M	71.8M	71M	103.3M	-77.5M
Total Equity	274.2M	194M	160.2M	123M	307.4M	286.4M	476.4M	342.9M	352.9M	360.2M	347.8M	122.2M	45.8M	69.2M	29.6M	64.9M	71.8M	71M	103.3M	-77.5M
SUMMARY
Total Liabilities & Equity	949.9M	785M	777.9M	724.2M	905.1M	886.5M	850.2M	790M	627M	1B	908.4M	210M	127.6M	110.1M	69.8M	112.6M	85.4M	128.8M	167.1M	59.6M
Total Investments	79.5M	36.2M	39.2M	144.8M	237.3M	320M	309.9M	424.4M	309.5M	143.3M	144.5M	145.1M	38.4M	65.2M	30M	77.9M	58.9M	93.1M	117.3M	42.6M
Total Debt	483.3M	443.6M	445.1M	452.1M	440.1M	441.7M	210.2M	321.7M	164.5M	154.5M	41.6M	14.4M	14.5M	697K	1M	2.3M	3.9M	1.2M	2.7M	3.6M
Net Debt	269.3M	229.9M	198.1M	303.3M	194.9M	278.5M	67.4M	242M	115.4M	-32.6M	-27.9M	-9.7M	-29.2M	-33.3M	-24.6M	-27.2M	-15.4M	-26.9M	-41.5M	-8.6M
Shares Outstanding	308,533,548	308,533,548	308,533,548	308,533,548	308,533,548	308,533,548	308,533,548	308,533,548	308,533,548	308,533,548	308,533,548	308,533,548	308,533,548	308,533,548	308,533,548	308,533,548	308,533,548	308,533,548	308,533,548	308,533,548

SEC Filings

FOLD - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	April 27, 2026	April 27, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 23, 2026	April 23, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 03, 2026	March 03, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 20, 2026	February 20, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 20, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	January 26, 2026	January 26, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 19, 2025	December 19, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 04, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 04, 2025	November 04, 2025	2025	View Filing
8-K 8-K 2025 N/A	July 31, 2025	July 31, 2025	2025	View Filing

Showing 1 to 10 of 437 filings

Related Guides

Blog Categories

Continue your FOLD research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.